Acadia have just released a filing announcing the appointment of Albert Kildani to the role of SVP, Investor Relations and Corporate Communications, excerpt below:
“I’m excited to join Acadia during this time of transformational growth as we deliver two important and commercially available therapeutics in areas of high unmet medical need to the patient community,” said Mr. Kildani. “The ongoing strength of the DAYBUE™ (trofinetide) launch, combined with our increasingly cash-flow positive NUPLAZID® (pimavanserin) franchise and our deep pipeline with upcoming data readouts position Acadia for long-term growth as we develop new therapies for patients and their families.”
Link to announcement: https://ir.acadia.com/news-releases/news-release-details/acadia-pharmaceuticals-appoints-albert-kildani-senior-vice
On a side note, a reminder that Acadia is presenting at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit, in just under 24 hours, and I hope to have some nuggets to share about trofinetide for those that can’t listen in.
Acadia have just released a filing announcing the appointment of...
-
- There are more pages in this discussion • 143 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.25 |
Change
-0.100(0.81%) |
Mkt cap ! $1.565B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.25 | $12.02 | $3.677M | 302.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1579 | $12.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.26 | 1199 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |